The company said its Q3 2025 revenue rose 54% year over year to $17,600.8 million, from $11,439.1 million a year earlier. It said the increase was driven by 62% volume growth, partially offset by a 10% decline due to lower realized prices.

1. 01

   The company said its Q3 2025 revenue rose 54% year over year to $17,600.8 million, from $11,439.1 million a year earlier. It said the increase was driven by 62% volume growth, partially offset by a 10% decline due to lower realized prices.

2. 02

   Eli Lilly said gross margin for Q3 2025 rose 57% to $14.59 billion, or 82.9% of revenue. It said research and development expenses increased 27% to $3.47 billion, or 19.7% of revenue.

3. 03

   The company said it raised its full-year 2025 revenue outlook to $63.0 to $63.5 billion from its prior outlook of $60.0 to $62.0 billion. Reported EPS guidance is $21.80 to $22.50, and non-GAAP EPS guidance is $23.00 to $23.70.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.